Patrick Soon-Shiong makes a $20M investment in $SRNE at $5.8 - certainly a encouraging development for the potential Abraxane competitor...
— Ian Estepan (@ianestepan) December 15, 2014
@VikramKhanna_ The goal, however, is to get quality in the bargain bin.
— David Sobek (@dsobek) December 15, 2014
$BLUE raise
— Ian Estepan (@ianestepan) December 15, 2014
@PropThinker if they did it last week they coulda raised a billion
— Red Acre Investments (@redacre) December 16, 2014
$cycc it's over
— J Morgan (@powerstocks) December 16, 2014
$ASPX ph3 study for Huntington's chorea (involuntary movements) met primary endpoint, ND filing expected mid-2015.
— Caroline Chen (@CarolineYLChen) December 16, 2014
@AF_biotech happy too. but for now bask in your glory. and give the kids the money in the 529
— daviesbj (@daviesbj) December 16, 2014
Hey kudos to @JNapodano and @AF_biotech both for conviction on $ASPX. There's probably more of you out there, but these two have been vocal.
— PropThinker (@PropThinker) December 17, 2014
Nice run into the close for $CUR up .33 to 2.70. A 14% gain on the day.
— BiopharmHunter (@BiopharmHunter) December 17, 2014
$SCTPF Trillium Therapeutics to List Common Shares on Nasdaq Capital Market Under the Symbol $TRIL
— Bio Stocks™ (@BioStocks) December 18, 2014
Roth lowers $meip PT from $22 to $14.
— Joe (@Drchik23) December 18, 2014
Guessing $achn inbox is getting flooded by call holders. Release the data damn it!!
— Festo (@Festo50) December 18, 2014
Tomorrow… big day? $ABBV $ENTA HepC drug approval decision. $OREX CHMP decision. And maybe even $ACHN data. Oh, and $JUNO trading!
— Adam Feuerstein (@adamfeuerstein) December 18, 2014
$JUNO is our dotcom. This open tomorrow is going to be nuts.
— Brad Loncar (@bradloncar) December 18, 2014
$BLCM opens up 30% at around $24.
— Damian Garde (@DamianFierce) December 18, 2014
Gr8 quote from public biotech exec: "We raised 10 Series A rounds in 4 hours", referring to ease of follow-on offering. Capital is flowing
— Bruce Booth (@LifeSciVC) December 18, 2014
Abx back, roaring in '14. More I think abt it if $TTPH really does get acq $1B+ $CEMP data readout could setup like ACHN has post IDIX
— Vikram Khanna (@VikramKhanna_) December 18, 2014
$IBB amazing.
— BioBounce.com (@BioBounce) December 18, 2014
@adamfeuerstein There's a scoring system that owners and vets use called the Canine Brief Pain Inventory.
— Brad Loncar (@bradloncar) December 18, 2014
ironic that $SLXP shareholders are pushing for a sale when mgmt was trying to do exactly that...and it resulted in the inventory 'discovery'
— zach (@zbiotech) December 18, 2014
$FMI Init at WF 30-32 PT and outperform
— j l (@lomu_j) December 19, 2014
What a day for Roche Discontinue gantenerumab P3 http://t.co/VCJ30t9smt MARIANNE missed PFS superiority endpt http://t.co/PtxnPTzfWo $IMGN
— Andy Biotech (@AndyBiotech) December 19, 2014
if $ACHN releases data tonight after market closes - lotta options holders gonna be real mad. Tick Tock
— Red Acre Investments (@redacre) December 19, 2014
Family overheard phone conversation last night. Hah! $JUNO pic.twitter.com/FUIYr5bxi9
— PropThinker (@PropThinker) December 19, 2014
Ouch. Bad day for $IMGN I like mgmt personally, but could never get my head around the valuation. Was wrong for 5yrs straight as it went up.
— David Miller (@AlpineBV_Miller) December 19, 2014
$TKMR the heart of the company has left. no explanation provided.
— Dirk Haussecker (@RNAiAnalyst) December 19, 2014
@AndyBiotech @alexlash only an ex $dndn can come up with that lol
— NathanAaron (@NathanAhron) December 19, 2014
Should I take out 2 or 3 additional mortgages on my house to buy $JUNO. It's that easy, right?
— David Sobek (@dsobek) December 19, 2014
TULIP MANIA is in full force today.
— Sally Church (@MaverickNY) December 19, 2014
$SRPT Talking to maxs IV nurse today- she is noticing an increase in hand strength- specifically opening and then crushing a soda can
— jenn mcnary (@jennmcnary) December 19, 2014
Fourth year-to-date test of 1200 for RUT / $IWM - how bad does she want it? pic.twitter.com/fU4uo9KuS0
— Downtown Josh Brown (@ReformedBroker) December 19, 2014
$ACST OUT here at $0.61 for -6% loss on the trade. Great come back, stock trading up +75% from lows less than a month ago. #comeback
— TurboResearch (@TurboResearch) December 19, 2014
betting against #alzheimers drugs has been the easiest trade in biotech land for the last decade $MDVN $PFE $BIIB $LLY $ELN
— Dan Rosenblum (@sharkbiotech) December 19, 2014
Leer: Code assigned to $EXAS's Cologuard, G0464, is confusing. National limit set for this code is $364.61, which is well below $502
— Ian Estepan (@ianestepan) December 19, 2014
$OREX jan 7 puts don't look too out of line. If that's your thing and you are an evil shortie
— DeadCatBill (@getbillasap) December 19, 2014
$JUNO Day 1 looking like $BLCM Day 1... $BLCM almost back to IPO price vs open
— LifeSciencesMkt (@LifeSciencesMkt) December 19, 2014
— Adam Feuerstein (@adamfeuerstein) December 19, 2014
$EXAS Reimbursement Code Update Seen as Clerical Error: Canaccord
— Ian Estepan (@ianestepan) December 19, 2014
$RMTI just another day.. 8.10 area holds and stock bounces back cc @SheffStation
— Amit Gupta (@amitp_gupta) December 19, 2014
@bradloncar @MarkSchoenebaum I follow over 500 people in my "BIOTECH" list. Large portion are academic doctors...huge value add
— Colfax (@ColfaxCapital) December 19, 2014
@bradloncar @MarkSchoenebaum yes- it's an old-fashioned world view. Social media is valid and Darwinian: quality of view matters > title
— Oli Rayner (@oli_rayner) December 19, 2014
@pennystocksusa The $ZGNX block of 1.9 million shares was @ $1.16- $1.12 & it should be the index rebalance at the closing
— Joe (@GantosJ) December 19, 2014
#FDA PR for $CBST #Zerbaxa approval http://t.co/lb20H1mypl $MRK #pharma #biotech #antibiotics
— Donna Young (@ScripDonnaDC) December 19, 2014
$EXAS shorties all worked up over nothing... 530pm est PR confirming CMS says they made a mistake, $500.76 will be the pricing.
— Shane Blackmon (@shaneblackmon) December 19, 2014
$EXAS got long shares to cover my $28 puts. Now rip all you want. I'm boxed in. Actually better for me if it rips up to $28.50s
— Rick (@Skipjackrick) December 19, 2014
ABBVIE HEP C DRUG WILL COST $83,319 $ABBV $GILD
— Drew Armstrong (@ArmstrongDrew) December 19, 2014
This past week: $IBB +3.63%, $XBI +3.6% YTD: $IBB +39.7%, $XBI +46.19%
— 23aloha (@23aloha) December 20, 2014
Not starting a price war = favor MT @ArmstrongDrew don't know if $ABBV did the drug industry any favors, in terms of complaints about price.
— Matthew Herper (@matthewherper) December 20, 2014
Im hoping i get the same flush fill on zsph, rlyp that i got on otic
— Randy (@lipscrl) December 20, 2014
2014...For every $itmn $agio $blue...there was $arwr $tkmr $imgn $epzm $glyc $fomx waiting to balance out
— The Saint (@SimanTemplar) December 20, 2014
@Drchik23 @Lin_ling_88 @genefj @trinijhart @DewDiligence I LOVED THE PRICING BY $ABBV protects industry pricing power for all assets
— Dr. Paul DeSantis (@DrPaulyDeSantis) December 20, 2014
In pharma everybody loses in a price war. Can't take your competitor out of the mkt and then rise prices back. Inconceivable w $GILD & $ABBV
— Juan P. Serrate, DVM (@JPZaragoza1) December 20, 2014
UPDATED: AbbVie wins blockbuster hep C approval, but shuns a deep discount on price $ABBV $GILD http://t.co/gmGeOiqqaC
— John Carroll (@JohnCFierce) December 20, 2014
@JohnCFierce $ABBV will offer discounts to win share but the $83K sticker price was not what PBMs and insurers needed to push $GILD around.
— Adam Feuerstein (@adamfeuerstein) December 20, 2014
my best trade last week (on 12/12) was when I tried to buy 100 $SRPT weekly $15 calls for .25 and only 9 filled. lucky
— DeadCatBill (@getbillasap) December 20, 2014
Sold $POZN for 12% loss. Not bad for a CRL
— Stan D'Andrea, Ph.D. (@stanleydandrea) December 18, 2014